Profil
Vincent Groppi is currently the Chief Executive Officer at Oricula Therapeutics LLC.
Prior to this, he worked as the Vice President at Essen BioScience, Inc. from 2007 to 2013.
Postes actifs de Vincent Groppi
| Sociétés | Poste | Début |
|---|---|---|
Oricula Therapeutics LLC
 Oricula Therapeutics LLC BiotechnologyHealth Technology Oricula Therapeutics LLC develops medication to prevent hearing loss. Its products is ORC-13661, a medicine to preserve hearing during aminoglycoside therapy, has completed preclinical development and has been approved to move into early human testing for safety, tolerability and pharmacokinetics. The company was founded in 2013 and is headquartered in Seattle, WA. | Directeur Général | - |
Anciens postes connus de Vincent Groppi
| Sociétés | Poste | Fin |
|---|---|---|
Essen BioScience, Inc.
 Essen BioScience, Inc. Medical SpecialtiesHealth Technology Essen Bioscience, Inc. specializes in developing and manufacturing instruments, software, reagents and consumables for real-time live-cell imaging and data analysis. Its cell imaging and electrophysiology products are used in academic and industrial laboratories. The company was founded by Kirk Schroeder and Brad Neagle in 1999 and is headquartered in Ann Arbor, MI. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Essen BioScience, Inc.
Essen BioScience, Inc. Medical SpecialtiesHealth Technology Essen Bioscience, Inc. specializes in developing and manufacturing instruments, software, reagents and consumables for real-time live-cell imaging and data analysis. Its cell imaging and electrophysiology products are used in academic and industrial laboratories. The company was founded by Kirk Schroeder and Brad Neagle in 1999 and is headquartered in Ann Arbor, MI. | Health Technology |
Oricula Therapeutics LLC
Oricula Therapeutics LLC BiotechnologyHealth Technology Oricula Therapeutics LLC develops medication to prevent hearing loss. Its products is ORC-13661, a medicine to preserve hearing during aminoglycoside therapy, has completed preclinical development and has been approved to move into early human testing for safety, tolerability and pharmacokinetics. The company was founded in 2013 and is headquartered in Seattle, WA. | Health Technology |
